ILLUMINATE-206 TRIAL | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website
  • Limited Premium Membership Offer: Lifetime @ $399 5-yr @ $199 2-yr @ $99


  • Membership Drive Update:
     Thanks to continued support from loyal customers like you, we're now up to 24% of our "pandemic survival" goal! 

IDRA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1640 of 1661  at  6/2/2020 8:38:41 AM  by

raferjack


ILLUMINATE-206 TRIAL

 
IDERA PHARMACEUTICALS ANNOUNCES PRELIMINARY DATA FROM AND PLANNED CONTINUATION OF THE ILLUMINATE-206 TRIAL FOR THE TREATMENT OF MICRO-SATELLITE STABLE COLORECTAL CANCER

EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of ILLUMINATE-206, a Phase 2, open-label, multi-center study to evaluate tilsotolimod in combination with Opdivo® (nivolumab) and Yervoy®* (ipilimumab) in immunotherapy-naive micro-satellite stable colorectal cancer (MSS-CRC) patients. Based on data to date, the Company plans to expand the study to further evaluate this triplet combination in MSS-CRC.

To investigate the safety profile of this triplet combination, ILLUMINATE-206 was designed with a stepwise approach to Yervoy® dosage. Patients in this initial safety cohort of the study, many of whom were heavily pre-treated and rapidly progressing, received 8 mg of intratumoral tilsotolimod and 3 mg/kg of intravenous (IV) Opdivo® every 2 weeks, along with 1 mg/kg of IV Yervoy® every 8 weeks. This regimen was generally well tolerated; no patients discontinued treatment due to adverse events (AEs) and none experienced Grade 4 or 5 AEs. One patient experienced stable disease per RECIST v1.1 criteria, and 9 patients progressed as defined by RECIST v1.1. Investigators reported that 6 of the progressing patients had stability or reduction in size of injected lesions and 6 had stability or reduction in overall size of uninjected lesions.

Based on these results, the Company plans to enroll additional patients in this MSS-CRC cohort of ILLUMINATE-206. Planned changes in the study design intended to improve potential outcomes in this patient population include increasing the frequency of Yervoy® dosing and limiting the number of allowed prior lines of treatment to two or fewer. Enrollment of the next 10 patients is targeted to begin in the fourth quarter of 2020, with data anticipated in the second quarter of 2021. Pending data from those patients, the trial may be expanded further.

“We are encouraged by the initial safety profile of this first-time triplet combination,” stated Elizabeth A. Tarka, M.D., Idera’s Chief Medical Officer. “We look forward to continuing to explore the potential clinical benefit of tilsotolimod in combination with ipilimumab and nivolumab in MSS-CRC, possibly yielding a treatment alternative for these patients with few current options.”



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 93
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1642 Re: ILLUMINATE-206 TRIAL - The $64,000 Question ... auh2oman 0 6/2/2020 9:41:02 AM






Financial Market Data provided by
.


Loading...